Strong Start to Fiscal 2025

F. Hoffmann-La Roche AG announced a promising start to fiscal 2025, with first-quarter sales hitting 15.4 billion Swiss francs. This marks a 7% increase in Swiss francs and a 6% rise at constant exchange rates (CER) compared to the previous year.

Pharmaceuticals Division Leads Growth

The pharmaceuticals division stood out with an 8% growth at CER, reaching 11.95 billion Swiss francs. Meanwhile, the diagnostics division maintained stability with sales of 3.49 billion Swiss francs, mirroring last year's figures.

CEO's Vision for Expansion

"We had a good start to the year with Group sales increasing by 6% at constant exchange rates and we achieved a number of important milestones," stated CEO Thomas Schinecker. Emphasizing Roche's commitment to innovation, he highlighted plans to invest USD 50 billion in the US, bolstering its presence with over 25,000 employees, 15 R&D, and 13 manufacturing sites.